Developing collaborative partnerships with Chinese pharmaceutical companies to discover and develop new drugs from traditional Chinese medicines to treat serious gastrointestinal diseases

与中国制药公司建立合作伙伴关系，发现和开发治疗严重胃肠道疾病的中药新药

• 批准号: 132652
• 金额: $ 1.53万
• 依托单位: CURILEUM DISCOVERY LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=132652
• 关键词: Developing; collaborative; partnerships; Chinese; pharmaceutical

Curileum Discovery Ltd is an emerging regenerative medicine company in London discovering and developing drugs to cure serious gastrointestinal (GI) diseases. Imbalances in the number and/or functions of cells underpin GI diseases. Current therapies treat the consequences of these imbalances and have a worldwide market exceeding £25 bn. Curileum's drug discovery platform targets stem cells, rare cells responsible for lifelong tissue renewal, to more effectively regulate cell production and function. Curileum provides the front-end drug discovery module to plug into its pharmaceutical partners' development pathway. Traditional Chinese medicines (TCMs) that treat serious GI diseases provide a rich source for new patentable drugs. Curileum will "modernise TCMs" by applying our state-of-the-art GI stem cell assays in London to isolate and develop the active components in TCMs in partnerships with Chinese pharmaceutical companies. Innovate UK's Global Cooperation Feasiblity Study provides the opportunity for Curileum to meet with Chinese pharmaceutical companies to develop collaborative partnerships.

Curileum Discovery有限公司是伦敦一家新兴的再生医学公司，致力于发现和开发治疗严重胃肠道疾病的药物。细胞数量和/或功能的不平衡是胃肠道疾病的基础。目前的治疗方法可以治疗这些失衡的后果，其全球市场规模超过250亿英镑。Curileum的药物发现平台针对干细胞（负责终身组织更新的罕见细胞），以更有效地调节细胞生成和功能。Curileum提供前端药物发现模块，以插入其制药合作伙伴的开发路径。治疗严重胃肠道疾病的中药为可申请专利的新药提供了丰富的来源。Curileum将与中国制药公司合作，在伦敦应用我们最先进的胃肠道干细胞检测技术，分离和开发中药中的有效成分，从而“使中药现代化”。创新英国的全球合作可行性研究为Curileum与中国制药公司建立合作伙伴关系提供了机会。